'/%3e%3ccircle%20cx='256'%20cy='236'%20r='169'%20fill='none'%20stroke='%23FF7A4A'%20stroke-width='4'/%3e%3cpath%20d='M60,400%20C200,370%20340,330%20470,290%20C478,294%20474,304%20466,306%20C340,350%20200,392%2074,416%20C58,418%2054,404%2060,400%20Z'%20fill='url(%23sw)'/%3e%3c/svg%3e)
Kisspeptin-10
10 mg
Price to be confirmed
GIP,GLP-1 and glucagon receptor triple agonist · Research reagent
Retatrutide
GLP-3 is a nickname for retatrutide. It targets three receptors, GLP-1, GIP and glucagon, and is being studied in clinical trials on metabolism and body weight.
Price to be confirmed
Vial discount: 5% off at 3, 10% at 5, 20% at 10 eligible single vials, any mix. Applied automatically in the cart.
Interac e-Transfer
$9.99 shipping, free from $250 · Ships from Canada · Canada only
Shipping and returns: Ships next business day from Canada · $9.99 shipping, free from $250 · Arrives right or we make it right
For research use only. Not for human consumption.
Independent lab report
Lab report: coming with this batch (Testides HPLC + LC-MS).
About Retatrutide
Retatrutide, also published as Retatrutide and LY3437943, is catalogued here as: GIP, GLP-1 and glucagon receptor triple agonist. GLP-3 is a nickname for retatrutide, studied in adults for metabolic and body-weight outcomes. It targets GLP-1, GIP and glucagon receptors: three targets, not three established benefits. GLP-3 is the informal catalogue name used here for retatrutide, a multi-receptor peptide agonist studied in metabolic research. The “3” refers informally to three named targets: GLP-1, GIP and glucagon receptors. GLP-3 is not itself a scientific receptor name, and receptor activity and clinical outcomes are separate questions. GLP-3 is a nickname for retatrutide. It targets three receptors, GLP-1, GIP and glucagon, and is being studied in clinical trials on metabolism and body weight.
Metabolic research of this kind uses randomized, placebo-controlled trials with defined populations and durations, measuring body-weight endpoints together with adverse events such as gastrointestinal symptoms and heart-rate changes.
A 2023 phase 2 randomized, placebo-controlled trial in 338 adults over 48 weeks reported lower body-weight outcomes in the study arms, along with gastrointestinal adverse events and heart-rate increases.
Human trial literature: Jastreboff et al. (NEJM, 2023) randomized 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week phase 2 trial. Receptor activity concerns metabolic signalling; measured weight change is a separate endpoint, not proof of an appetite mechanism or a BLOOM product effect.
ABIDE lists Retatrutide as a vial in 10 mg, with pack sizes of 1, 3, 5 and 10. Prices are shown in Canadian dollars, and orders ship from Canada by tracked Canadian service.
A lab report for Retatrutide is available on request. ABIDE does not display a report until it is matched to the exact compound and strength.
Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.
